GSK plc (NYSE: GSK) has entered into an agreement to acquire a trispecific T-cell engager program from ChImagen Biosciences, targeting the treatment of multiple myeloma.
The total potential value of the deal reaches up to $750 million, according to GSK, with payments structured around success-based development and commercial milestones.
Under the terms of the agreement, GSK will receive full global rights to ChImagen’s T-cell engager program, giving the company exclusive control over its development and commercialization.
GSK intends to advance the asset into Phase I clinical trials in 2027, marking a significant step forward in the company’s oncology pipeline expansion.
Multiple myeloma is a cancer of plasma cells in the bone marrow and remains a disease with significant unmet medical need despite recent therapeutic advances.
Trispecific T-cell engagers represent a next-generation class of immunotherapy, designed to simultaneously bind multiple targets and redirect immune cells to attack cancer cells more precisely.
ChImagen Biosciences is eligible to receive milestone payments tied to the program’s development and commercial progress, with the structure incentivizing long-term collaboration toward successful outcomes.
GSK announced the ChImagen agreement on September 15, 2026, reinforcing the company’s strategy of building out its oncology capabilities through targeted licensing and acquisition deals.
On the trading front, Lang and Schwarz showed GSK stock at EUR 20.83 during weekend trading on October 3, 2026, unchanged at 0.00 percent versus the EUR 20.83 close recorded on October 2, 2026.
Lang and Schwarz listed a bid of EUR 20.71 and an ask of EUR 20.95 at the time of the quoted price, with the next regular Xetra trading session scheduled for October 5, 2026.
The ChImagen acquisition underscores GSK’s broader push into cutting-edge immunotherapy platforms as competition in the multiple myeloma treatment space continues to intensify among major pharmaceutical players.
